MedTrace Logo

Tenofovir in Asian Chronic Hepatitis B Patients

NCT01728935 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2014-12-30

No results posted yet for this study

Summary

Tenofovir (TDF) has been demonstrated to have potency antiviral against the hepatitis B virus (HBV) in various multiple-centre trials, with no cases of resistance encountered. However, its efficacy and resistance profile in the Asian population, which constitute the majority of chronic hepatitis B (CHB) patients, is unknown. Compared to other nucleoside analogues, TDF has been associated with relatively high rates of hepatitis B surface antigen (HBsAg) seroclearance. It would be interested to see if this could be reproduced. The investigators plan to report the serologic and virologic results of our 140 nucleoside analogue-experienced patients who were commenced on TDF.

Conditions

Interventions

DRUG

Tenofovir disoproxil

Tenofovir disoproxil 300mg daily

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Man-Fung Yuen, MD · The University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-11-30
Completion
2013-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01728935 on ClinicalTrials.gov